Anixa Biosciences to Present Ovarian Cancer CAR-T Therapy Trial at Gynecologic Oncology Conference

Moffitt Cancer Center principal investigator to discuss status of Anixa's ongoing Phase 1 clinical trial of lira-cel.

Mar. 30, 2026 at 2:18pm

Got story updates? Submit your updates here. ›

Anixa Biosciences announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. Dr. Wenham's presentation will discuss the clinical trial design, objectives, and current status of Anixa's Phase 1 trial of lira-cel, a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer.

Why it matters

Anixa's lira-cel therapy represents a novel approach to treating ovarian cancer, using a unique CAR-T technology that targets the FSHR receptor instead of traditional antibody-based approaches. Presenting the latest updates on this clinical trial at the prestigious SGO conference will allow Anixa to share its progress with leading experts in gynecologic oncology and potentially generate further interest and collaboration opportunities.

The details

Lira-cel, Anixa's CAR-T therapy for recurrent ovarian cancer, uniquely targets the FSHR receptor which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. Anixa is developing lira-cel in collaboration with Moffitt Cancer Center, a world leader in cancer immunotherapy treatments.

  • The SGO Annual Meeting on Women's Cancer will be held April 10 – 13, 2026, in San Juan, Puerto Rico.
  • Anixa's ongoing Phase 1 clinical trial of lira-cel is currently enrolling patients (ClinicalTrials.gov NCT05316129).

The players

Anixa Biosciences, Inc.

A clinical-stage biotechnology company focused on the treatment and prevention of cancer, developing lira-cel, a novel CAR-T therapy for recurrent ovarian cancer.

Dr. Robert Wenham

Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 trial.

Moffitt Cancer Center

A world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T and tumor infiltrating lymphocytes (TILs), and Anixa's collaborator on the development of lira-cel.

Got photos? Submit your photos here. ›

What they’re saying

“Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer”

— Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Anixa's novel CAR-T therapy targeting the FSHR receptor represents a promising new approach to treating recurrent ovarian cancer, and the presentation of the latest clinical trial data at the prestigious SGO conference will help raise awareness and generate further interest in this innovative therapy.